Defining clinically meaningful improvement in molluscum contagiosum
- PMID: 37871806
- DOI: 10.1016/j.jaad.2023.10.033
Defining clinically meaningful improvement in molluscum contagiosum
Keywords: clinical meaningfulness; infectious diseases; molluscum contagiosum; nitric oxide; patient-reported outcome measures; pediatrics.
Conflict of interest statement
Conflicts of interest Dr Hebert has received research grants paid to the McGovern School of Medicine from AbbVie, Arcutis, Novan, and Pfizer; has received honoraria from Pfizer, Arcutis, Incyte, Novan, Ortho Dermatologics, Amyrt, Galderma, Almirall; and is a member of Data Safety Monitoring Boards for GSK, Ortho Dermatologics, and Sanofi Regeneron. Dr McLeod is an employee of RTI Health Solutions, which received funding from Novan, Inc. for data analysis. Dr Siegfried has received research support paid to the Saint Louis University School of Medicine from Regeneron and Amgen; honoraria from AbbVie, Alphyn, ASLAN Pharmaceuticals, Boehringer Ingelheim, Cara Therapeutics, Incyte, Leo, NobelPharma, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB, and Verrica; and is a salaried member of Data Safety Monitoring Boards for Leo, Novan, Pfizer, UCB, and Esperare. Dr Silverberg has received honoraria from Sanofi/Regeneron, Novan, Verrica, Pfizer, and Incyte. Drs. Cartwright and Maeda-Chubachi and Ms. Enloe are employees of and stockholders in Novan, Inc. Substantive editing was provided by Dana L. Randall, MS, PharmD, Intuitive Graphite, Inc. and funded by Novan, Inc.
Comment in
-
Searching for a pox on the house of molluscum.J Am Acad Dermatol. 2024 Feb;90(2):255-256. doi: 10.1016/j.jaad.2023.11.021. Epub 2023 Nov 24. J Am Acad Dermatol. 2024. PMID: 38007037 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
